Progenitor cells from untreated CML patients exhibit diminished CD58 expression, but surface CD58 expression could be at normal levels or even exceed normal levels after IFN-α treatment (197). This evidence concerns the gene CD58 and chronic myelogenous leukemia, BCR-ABL1 positive.